Operating Margin
Ipsen SA

26%
Current
23%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26%
=
Operating Profit
977.8m
/
Revenue
3.8B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Ipsen SA
PAR:IPN
9.8B EUR
26%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
499.4B USD
27%
CH
Roche Holding AG
SIX:ROG
260.8B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
212.9B GBP
24%
CH
Novartis AG
SIX:NOVN
210.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
265.2B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
212.8B USD
11%
US
Pfizer Inc
NYSE:PFE
142.2B USD
29%
No Stocks Found

Ipsen SA
Glance View

Market Cap
9.9B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26%
=
Operating Profit
977.8m
/
Revenue
3.8B
What is the Operating Margin of Ipsen SA?

Based on Ipsen SA's most recent financial statements, the company has Operating Margin of 26%.

Back to Top